公开(公告)号：US20170199205A1

公开(公告)日：2017-07-13

申请号：US15463274

申请日：2017-03-20

Applicant: STC.UNM

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB)damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US09579381B2

公开(公告)日：2017-02-28

申请号：US14426543

申请日：2013-09-06

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/4409 ,  A61K41/00

CPC classification number: A61K41/0052 ,  A61K31/4409

Abstract: The invention provides method of treating a subject suffering from, or at risk of developing, a Mycobacterium infection by administering to the subject a therapeutically-effective amount of isotopically labeled isoniazid and/or ethionamide, or an analog, derivative or prodrug thereof, and exposing the subject to a magnetic field.

Abstract translation: 本发明提供了通过向受试者施用治疗有效量的同位素标记的异烟肼和/或乙硫异烟胺或其类似物，衍生物或前药，以及暴露于受试者的方法，治疗患有或有发展为分枝杆菌感染风险的受试者 受到磁场的影响。

公开(公告)号：US20150246126A1

公开(公告)日：2015-09-03

申请号：US14426543

申请日：2013-09-06

Applicant: Graham TIMMINS ,  Seong Won CHOI ,  STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K41/00 ,  A61K31/4409

CPC classification number: A61K41/0052 ,  A61K31/4409

Abstract: The invention provides method of treating a subject suffering from, or at risk of developing, a Mycobacterium infection by administering to the subject a therapeutically-effective amount of isotopically labeled isoniazid and/or ethionamide, or an analog, derivative or prodrug thereof, and exposing the subject to a magnetic field.

Abstract translation: 本发明提供了通过向受试者施用治疗有效量的同位素标记的异烟肼和/或乙硫异烟胺或其类似物，衍生物或前药，以及暴露于受试者的方法，治疗患有或有发展为分枝杆菌感染风险的受试者 受到磁场的影响。

公开(公告)号：US10000787B2

公开(公告)日：2018-06-19

申请号：US14434509

申请日：2013-10-08

Applicant: STC.UNM ,  LOS ALAMOS NATIONAL SECURITY, LLC

Inventor： Graham Timmins ,  Louis Pete Silks

IPC: C12Q1/04 ,  C12Q1/02 ,  A61B5/083 ,  G01N33/497 ,  G01N33/569 ,  G01N33/60 ,  G21H5/02 ,  A61B5/08 ,  A61B5/145 ,  A61B5/20

CPC classification number: C12Q1/04 ,  A61B5/082 ,  A61B5/0836 ,  A61B5/14507 ,  A61B5/14546 ,  A61B5/207 ,  C12Q1/02 ,  G01N33/497 ,  G01N33/56911 ,  G01N33/60 ,  G01N2333/33 ,  G21H5/02

Abstract: The present invention is directed to methods of determining the presence or absence of a bacterial infection in a patient using isotopically-labeled tyrosine and/or isotopically-labeled p-hydroxyphenylacetic acid.

公开(公告)号：US09606129B2

公开(公告)日：2017-03-28

申请号：US14677053

申请日：2015-04-02

Applicant: STC.UNM

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: A61K39/395 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US20150275265A1

公开(公告)日：2015-10-01

申请号：US14434509

申请日：2013-10-08

Applicant: STC.UNM

Inventor： Graham Timmins ,  Louis Pete Silks

IPC: C12Q1/04

CPC classification number: C12Q1/04 ,  A61B5/082 ,  A61B5/0836 ,  A61B5/14507 ,  A61B5/14546 ,  A61B5/207 ,  C12Q1/02 ,  G01N33/497 ,  G01N33/56911 ,  G01N33/60 ,  G01N2333/33 ,  G21H5/02

Abstract: The present invention is directed to methods of determining the presence or absence of a bacterial infection in a patient using isotopically-labeled tyrosine and/or isotopically-labeled p-hydroxyphenylacetic acid.

Abstract translation: 本发明涉及使用同位素标记的酪氨酸和/或同位素标记的对羟基苯基乙酸来测定患者中细菌感染的存在或不存在的方法。

公开(公告)号：US20200237687A1

公开(公告)日：2020-07-30

申请号：US16778220

申请日：2020-01-31

Applicant: STC.UNM

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: A61K31/137 ,  A61K45/06 ,  A61K35/00 ,  A61K51/04 ,  A61K9/00 ,  C07C213/08 ,  A61K31/136 ,  A61P31/04 ,  A61P11/00 ,  C07C215/68 ,  A61K31/395 ,  C07C215/42 ,  C07B59/00 ,  A61P31/06 ,  A61K45/00

Abstract: The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an antophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

公开(公告)号：US20180296505A1

公开(公告)日：2018-10-18

申请号：US16015415

申请日：2018-06-22

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/16 ,  A61K9/00 ,  A61K31/4965 ,  A61K45/06

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

公开(公告)号：US20170056345A1

公开(公告)日：2017-03-02

申请号：US15119563

申请日：2015-02-18

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/16 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4965

CPC classification number: A61K31/16 ,  A61K9/0075 ,  A61K31/4965 ,  A61K45/06 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

Abstract translation: 在一个实施方案中，本发明提供了治疗患有或被怀疑患有分枝杆菌感染的受试者的方法，所述方法包括向受试者施用治疗有效量的脲酶抑制剂，任选地与一种 或更多的抗分枝杆菌剂。